Cara Therapeutics has announced the pricing of its underwritten public offering of 3,763,440 shares of its common stock at a public offering price of $18.60 per share.

The gross proceeds from the offering, before deducting the underwriting discounts and commissions and offering expenses payable by Cara Therapeutics, are expected to be approximately $70 million.